Becker's Healthcare August 28, 2024
In July, the FDA approved a new blood test for colorectal cancer screenings that was able to detect 83% of Stage 1, 2 or 3 colorectal cancers in studies.
But as Amol Akhade, MD, and medical oncologist, argues in an Aug. 27 commentary in Oncology News Central, the test is not accurate enough to surpass colonoscopies, long considered the gold standard in diagnosis.
“Finding a blood-based test to screen for cancer is a dream for every oncology researcher. Imagine a simple blood test that can detect precancerous lesions or Stage 1 cancer in asymptomatic individuals,” Akhade writes.
“This would greatly benefit both oncologists and patients, potentially reducing cancer-specific mortality in the long term. The catch is that...
Today's Sponsors
Today's Sponsor